CAESAREA, Israel--(BUSINESS WIRE)--Itamar-Medical, the world's leader of non-invasive devices for diagnosis of cardiovascular health, announced achievement of the next milestone of the international pharmaceutical company, Roche, to further develop the EndoPAT technology for pre-clinical trials. This is a continuation of the original announcement from December 2010.

The device developed will enable pharmaceutical companies in general to potentially integrate EndoPAT into a large number of drug development projects at a very early drug development stage.

Itamars EndoPAT technology serves as a vital, non-invasive diagnostic tool for measuring endothelial dysfunction – the early stage of arteriosclerosis in humans.

"Further to our work with Roche, this continued development strengthens Itamar-Medical's strategic direction that the EndoPAT can support translational medicine a further step towards the important trend of Personalized Medicine using Companion Diagnostics," said Dr. Dov Rubin, President and CEO of Itamar-Medical Ltd.

Dr. Koby Sheffy, Senior Vice President of Technology at Itamar-Medical added, "This advanced development positions the EndoPAT technology as a preferred technology in the development of cardiovascular drugs, from the early animal model stage and over the continued various development stages with humans."

About Itamar Medical

Itamar Medical Ltd. is a publicly-traded medical technology company utilizing PAT™ (Peripheral Arterial Tone) signal technology and applications. The PAT signal is a non-invasive "window" to both the cardiovascular and autonomic nervous systems. For more information, visit

Posted by Sean Fenske, Editor-in-Chief, MDT